<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002324</url>
  </required_header>
  <id_info>
    <org_study_id>200C</org_study_id>
    <secondary_id>1038</secondary_id>
    <nct_id>NCT00002324</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease</brief_title>
  <official_title>A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cells/mm3 and 2) 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with&#xD;
      zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment. To&#xD;
      evaluate the safety and tolerance of nevirapine alone or in combination with AZT.&#xD;
&#xD;
      SECONDARY: To compare the effects of the various treatment combinations on virologic and&#xD;
      immunologic markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part I, patients who have had prior AZT therapy receive either nevirapine or placebo in&#xD;
      combination with AZT. In Part II, patients who are nucleoside naive receive either nevirapine&#xD;
      or matching placebo. After 6 months, patients receive open-label nevirapine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>250</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  PCP prophylaxis (trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine),&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
          -  Antifungal prophylaxis with oral fluconazole or ketoconazole.&#xD;
&#xD;
          -  Antiviral prophylaxis for herpes simplex virus with &lt;= 1000 mg/day oral acyclovir.&#xD;
&#xD;
          -  Dilantin for prevention and treatment of seizures.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Asymptomatic HIV-1 infection, with positive serum antibody to HIV-1 as determined by&#xD;
             ELISA or Western blot.&#xD;
&#xD;
          -  CD4 count 200-500 cells/mm3 within 4-28 days prior to study entry.&#xD;
&#xD;
          -  No conditions indicative of AIDS.&#xD;
&#xD;
          -  None of the constitutional symptoms that are specifically excluded.&#xD;
&#xD;
          -  Prior AZT for 3-24 months (amended 04/04/94) immediately prior to study entry (Part I)&#xD;
             OR no prior AZT (Part II).&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Co-enrollment in a protocol involving another investigational drug or biologic is not&#xD;
             permitted.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy other than limited cutaneous basal cell carcinoma.&#xD;
&#xD;
          -  Psychiatric condition sufficient to impair compliance with protocol requirements.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Investigational drugs other than study drugs.&#xD;
&#xD;
          -  Systemic glucocorticoids and steroid hormones.&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Phenobarbital and other barbiturates.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Amoxicillin-clavulanate (Augmentin).&#xD;
&#xD;
          -  Ticarcillin clavulanate (Timentin).&#xD;
&#xD;
          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).&#xD;
&#xD;
        Patients with the following condition are excluded:&#xD;
&#xD;
        History of other clinically important disease (i.e., one that precludes participation in&#xD;
        the study).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral medications other than AZT.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Immunosuppressive or cytotoxic drugs or other experimental drugs.&#xD;
&#xD;
          -  Systemic glucocorticoids and steroid hormones.&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Phenobarbital and other barbiturates.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Amoxicillin-clavulanate (Augmentin).&#xD;
&#xD;
          -  Ticarcillin clavulanate (Timentin).&#xD;
&#xD;
          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).&#xD;
&#xD;
        Required (for patients in Part I):&#xD;
&#xD;
          -  Prior AZT at 500-600 mg daily for at least 3 months but not more than 24 months&#xD;
             immediately prior to study entry.&#xD;
&#xD;
        Chronic use of alcohol or drugs sufficient to impair compliance with protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Mem Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Hosp</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodgame Med Group</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Kansas School of Medicine</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chandler Med Ctr</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>405360084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City AIDS Research Consortium</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>641082792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative on AIDS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates Med and Mental Health</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Alfred F Burnside Jr</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson-Tebedo Community Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Research Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Physicians Inc</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollard R . Surrogate marker response to NVP/ZDV or ZDV in a blinded clinical trial: correlation to changes in HIV isolate phenotypic susceptibility to NVP and ZDV. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:113</citation>
  </reference>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Nevirapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

